Breaking News

AMA blasts BMI, Biogen's board faces a scandal, & an MIT scientist cleared of fraud finally speaks out

June 14, 2023
Reporter, Morning Rounds Writer
Good morning. In today's news, BMI gets downgraded by the AMA, Biogen's boardroom scandal tests its new CEO, and two studies underscore the unexpected nature of addiction and its treatment.

obesity

Citing 'historical harm,' AMA knocks BMI as a measure of health and obesity

The body mass index has long been criticized as an imperfect measure of health, but a policy adopted yesterday by the AMA may be the most consequential criticism of the long-controversial metric of obesity and health. At its annual meeting in Chicago, the dominant U.S. medical group urged doctors to downplay its use and acknowledging its role in "racist exclusion" and "historical harm." The policy says, "BMI cutoffs are based primarily on data collected from previous generations of non-Hispanic White populations and does not consider a person's gender or ethnicity," undermining accuracy.

The new policy recommends looking at other measures such as adiposity, body composition, and waist circumference and recognizes that risks differ both between and within demographic groups. BMI and weight have gotten renewed attention recently as new drugs that lead to significant weight loss such as Wegovy, Ozempic, and Mounjaro have exploded in popularity. STAT's Elaine Chen and Brittany Trang have more.


biotech

Biogen saddles new CEO with a boardroom scandal

Photo illustration of Chris Viehbacher
Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

Biogen has a new CEO but an old problem. When Chris Viehbacher (above), a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force who would stand up to its quarrelsome board. Instead, Biogen's board has handed him his first company crisis. Longtime director Alex Denner nominated Susan Langer, a biotech executive who is also the mother of his child, to succeed him. Biogen did not disclose the couple's relationship to shareholders.

"It's just disappointing to see after all the criticism that has been levied at the company," analyst Brian Skorney said. Just last week, Viehbacher told a packed crowd at a drug industry conference that he was getting along well with Biogen's directors. Langer's nomination will be voted on at a meeting set for June 26. STAT's Damian Garde and Adam Feuerstein have more.


addiction medicine

Teens were offered equine therapy more often than medication to treat addiction, study finds

Adolescents who are inpatients at opioid addiction treatment centers are more likely to be offered horseback riding than given full access to a common, highly effective addiction medication, a new JAMA study reports. Few Americans have convenient access to buprenorphine and methadone, two medications used to treat opioid addiction, STAT's Lev Facher reminds us. But access is particularly narrow among 16- and 17-year-olds.

The study found just 10.6% of facilities offered buprenorphine initiation and continued treatment while 25% of all facilities surveyed offered equine therapy, an approach not supported by evidence. "You expect that the sickest kids, the kids with the least access, are going to be the kids in these residential treatment centers," study co-author Caroline King told Lev. "And if they can't access bupe there, it might be a red flag that they also really can't access it in communities and outpatient providers. Read more.



Closer Look

Cleared of fraud and now free to speak, MIT professor asks what went wrong

A portrait of Ram SasisekharanMIT

There are two sides to this story, but for almost four years only one party could tell theirs. In 2019, MIT colleagues publicly accused Ram Sasisekharan (above) and his lab of falsifying research related to therapeutic antibodies for Zika virus and influenza. During a lengthy internal investigation that sidelined his work and decimated his team, he was required to remain silent. In March MIT's vice president for research said in an internal email that the investigation had concluded "with no finding of research misconduct for any of the submitted allegations."

Only one of Sasisekharan's accusers responded to requests for comment from STAT's Damian Garde, saying he stood by the allegations. For the three scientists — down from 18 — remaining in Sasisekharan's lab, it may not feel like it's over. For his part, Sasisekharan is asking what can be learned from his experience. "I've been through a negative journey, and I want something good to come out of this," he said. Read more.


politics

Walensky answers GOP questions as her CDC tenure nears its end

The shots were predictable and outgoing CDC Director Rochelle Walensky was able to parry them yesterday during a House hearing critical of her pandemic leadership. She was asked about her comments on whether Covid-19 vaccines prevent transmission of the disease, how much influence teachers' unions had over guidance for protocols in schools, how the agency collects data — and why she wasn't wearing a mask. 

Queried about gain-of-function research, she referred questions to the NIH. On CDC officials' relationships with social media companies regarding vaccine misinformation, she declined to comment while it's being litigated. When Rep. Marjorie Taylor Greene (R-Ga.) pressed her on whether she plans to work for Moderna or Pfizer, Walensky said she doesn't have plans after she leaves her position, and the CDC doesn't purchase vaccines. On masks, she pointed Rep. Debbie Lesko (R-Ariz.) to current hospitalization data. STAT's Rachel Cohrs has more


addiction and law enforcement 

A case for why we can't arrest our way out of the opioid crisis

They call it the "drug bust paradox": Police actions were followed by a large and sudden spike in opioid overdose deaths, researchers report in a new paper. And in the Indianapolis neighborhood they studied, not only did fatal overdoses double, but calls to 911 and use of naloxone, the overdose-reversal medication, also surged. Authors in the American Journal of Public Health hesitate to make a causal link between law enforcement and later drug deaths, but the association fits with what they hear in the field.

One possible explanation: When police officers arrest drug dealers, their regular customers lose their supply. Facing with agonizing withdrawal symptoms and with addiction treatment difficult to access, many simply find other dealers. "We're learning that it's not just the drugs in the drug supply — it's the fluctuation and unpredictability and the risk of misjudging your dose," study co-author Jennifer Carroll told STAT's Lev Facher. Read more.


On this week's episode of the "First Opinion Podcast," First Opinion editor Torie Bosch speaks with Gabriel Bosslet and Tracey Wilkinson about "good trouble" and lessons learned from what their friend Caitlin Bernard, an OB-GYN in Indiana, lived through after she said she'd performed an abortion on a 10-year-old Ohio girl who had been raped. Listen here.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Bitter infighting leads 15 chapters to break away from leading ALS advocacy group, STAT
  • Scalpel, forceps, bone drill: modern medicine in ancient Rome, New York Times
  • Are all calories created equal? Your gut microbes don't think so, Washington Post
  • Key House Republican escalates rhetoric against PBMs, STAT
  • Most early-stage breast cancer patients will be long-term survivors — study, The Guardian

Thanks for reading! More tomorrow,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments